|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RBP7 |
Gene summary for RBP7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RBP7 | Gene ID | 116362 |
| Gene name | retinol binding protein 7 | |
| Gene Alias | CRABP4 | |
| Cytomap | 1p36.22 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q96R05 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 116362 | RBP7 | GSM4909281 | Human | Breast | IDC | 3.53e-28 | 6.54e-01 | 0.21 |
| 116362 | RBP7 | GSM4909282 | Human | Breast | IDC | 2.89e-20 | 5.94e-01 | -0.0288 |
| 116362 | RBP7 | GSM4909285 | Human | Breast | IDC | 7.95e-06 | 1.91e-01 | 0.21 |
| 116362 | RBP7 | GSM4909293 | Human | Breast | IDC | 7.00e-05 | -2.25e-01 | 0.1581 |
| 116362 | RBP7 | GSM4909294 | Human | Breast | IDC | 1.78e-08 | -2.42e-01 | 0.2022 |
| 116362 | RBP7 | GSM4909296 | Human | Breast | IDC | 3.69e-10 | -2.46e-01 | 0.1524 |
| 116362 | RBP7 | GSM4909302 | Human | Breast | IDC | 7.28e-05 | -2.34e-01 | 0.1545 |
| 116362 | RBP7 | GSM4909304 | Human | Breast | IDC | 3.85e-08 | -2.46e-01 | 0.1636 |
| 116362 | RBP7 | GSM4909307 | Human | Breast | IDC | 3.62e-02 | -2.02e-01 | 0.1569 |
| 116362 | RBP7 | GSM4909308 | Human | Breast | IDC | 4.30e-03 | -2.26e-01 | 0.158 |
| 116362 | RBP7 | GSM4909309 | Human | Breast | IDC | 2.83e-02 | -2.16e-01 | 0.0483 |
| 116362 | RBP7 | GSM4909311 | Human | Breast | IDC | 1.75e-09 | -2.49e-01 | 0.1534 |
| 116362 | RBP7 | GSM4909312 | Human | Breast | IDC | 1.30e-06 | -2.23e-01 | 0.1552 |
| 116362 | RBP7 | GSM4909315 | Human | Breast | IDC | 1.78e-08 | -2.49e-01 | 0.21 |
| 116362 | RBP7 | GSM4909317 | Human | Breast | IDC | 2.82e-04 | -2.35e-01 | 0.1355 |
| 116362 | RBP7 | GSM4909319 | Human | Breast | IDC | 3.85e-08 | -2.42e-01 | 0.1563 |
| 116362 | RBP7 | NCCBC14 | Human | Breast | DCIS | 1.42e-04 | -2.31e-01 | 0.2021 |
| 116362 | RBP7 | NCCBC5 | Human | Breast | DCIS | 1.47e-06 | -2.49e-01 | 0.2046 |
| 116362 | RBP7 | P2 | Human | Breast | IDC | 3.03e-04 | -2.49e-01 | 0.21 |
| 116362 | RBP7 | DCIS2 | Human | Breast | DCIS | 4.21e-14 | -9.68e-02 | 0.0085 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RBP7 | SNV | Missense_Mutation | c.363N>A | p.Phe121Leu | p.F121L | Q96R05 | protein_coding | tolerated(0.64) | benign(0.039) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| RBP7 | SNV | Missense_Mutation | novel | c.78T>G | p.Ile26Met | p.I26M | Q96R05 | protein_coding | tolerated(0.06) | probably_damaging(0.988) | TCGA-AG-3726-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RBP7 | SNV | Missense_Mutation | c.232N>A | p.Leu78Met | p.L78M | Q96R05 | protein_coding | tolerated(0.13) | benign(0.123) | TCGA-AP-A0LG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RBP7 | SNV | Missense_Mutation | novel | c.376G>T | p.Val126Leu | p.V126L | Q96R05 | protein_coding | tolerated(0.08) | benign(0.027) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| RBP7 | SNV | Missense_Mutation | c.170N>A | p.Ser57Asn | p.S57N | Q96R05 | protein_coding | deleterious(0) | benign(0.037) | TCGA-CG-5721-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |